Daniel H Ahn DO M.S.
Gastrointestinal Cancer, Hematologic Oncology
Senior Associate Consultant, Assistant Professor
Join to View Full Profile
13400 E Shea BlvdScottsdale, AZ 85259
Phone+1 480-301-8000
Dr. Ahn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Ohio State UniversityM.S., Clinical Investigation, 2014 - 2016
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2013 - 2016
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2009 - 2011
Texas College of Osteopathic MedicineClass of 2008
Certifications & Licensure
AZ State License 2016 - 2027
TX State License 2011 - 2026
OH State License 2013 - 2017
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- ASCO GI Symposium Merit Award ASCO, 2016
- ASCO/CCF Young Investigator Award ASCO, 2015
Clinical Trials
- TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery Start of enrollment: 2017 Dec 11
- A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma Start of enrollment: 2018 Mar 07
- Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Start of enrollment: 2019 Feb 07
- Join now to see all
Publications & Presentations
PubMed
- CLO25-095: Baseline Genomic Alterations as Predictors of Response to Anti-HER2 Therapy in HER2-Amplified Advanced Colorectal Cancer (aCRC).Celine Hoyek, Angelo Pirozzi, Binbin Zheng, Naoko Lida, Ryne Ramaker
Journal of the National Comprehensive Cancer Network. 2025-03-28 - Sequential Treatment with Regorafenib and Trifluridine/Tipiracil ± Bevacizumab in Refractory Metastatic Colorectal Cancer in Community Clinical Practice in the USA.Daniel H Ahn, Tanios S Bekaii-Saab, Chengbo Yuan, Milena Kurtinecz, Xiaoyun Pan
Cancers. 2025-03-13 - Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.Daniel H Ahn, Maya Ridinger, Timothy L Cannon, Lawrence Mendelsohn, Jason S Starr
Journal of Clinical Oncology. 2025-03-01
Journal Articles
- Systemic Therapy and Sequencing Options in Advanced Hepatocellular CarcinomaMohamad Bassam Sonbol, Amit Mahipal, Zhaohui Jin, Kabir Mody, Mitesh J Borad, Daniel H Ahn, Tanios Bekaii-Saab, JAMA Oncology
- Targeting the Stroma in Pancreatic CancerDaniel H Ahn, Ramesh K Ramanathan, Annals of Palliative Medicine
Press Mentions
Neoadjuvant Chemotherapy Regimen Extends Survival in Pancreatic CancerJuly 14th, 2022- Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic CancerJune 8th, 2021
- Why Cardiff Oncology Stock Is Crashing TodayJanuary 15th, 2021
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
